Brief: Merus Presents Clinical Data On Zenocutuzumab (Zeno) In Nrg1-Fusion (Nrg1+) Cancer At The 2022 American Society Of Clinical Oncology (Asco) Annual Meeting (Oral Abstract)
05/06/2022 16:08
June 5 (Reuters) - Merus NV MRUS.O :
* MERUS PRESENTS CLINICAL DATA ON ZENOCUTUZUMAB (ZENO) IN
NRG1-FUSION (NRG1+) CANCER AT THE 2022 AMERICAN SOCIETY OF
CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING (ORAL ABSTRACT)
* MERUS NV - 34% OVERALL RESPONSE RATE IN 79 EVALUABLE
PATIENTS
WITH MEASURABLE DISEASE
* MERUS NV - TUMOR REDUCTION IN 70% OF PATIENTS
Source text for Eikon: ID:nGNX1NyKKv
Further company coverage: MRUS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab